Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901352 | 0.87 | OPRL1 (0.37) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL22221915 | 0.83 | OPRM1 (0.33) | OPRL1OPRM1 | |
| SCHEMBL23847242 | 0.81 | OPRM1 (0.34) | OPRL1OPRM1 | |
| SCHEMBL19426013 | 0.81 | OPRM1 (0.34) | OPRL1OPRM1 | |
| SCHEMBL25129589 | 0.80 | OPRM1 (0.35) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL25090277 | 0.79 | OPRM1 (0.36) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL27065392 | 0.79 | OPRL1 (0.38) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL24250686 | 0.78 | OPRL1 (0.36) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL19152235 | 0.78 | OPRM1 (0.33) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL24538124 | 0.77 | OPRM1 (0.31) | OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-08-12 | — | — | US | disclosed |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | OPRL1 4238/4885OPRM1 4710/4885SIGMAR1 4815/4885 |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | OPRL1 4380/4885OPRM1 4579/4885SIGMAR1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.